文献速递神经肌肉病

补体C5抑制剂雷夫利珠单抗在成人肌萎缩侧索硬化中的疗效与安全性:一项随机临床试验

Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2023-01-01

这项双盲、安慰剂对照、平行组、多国、随机的3期临床试验在17个国家81个ALS专科中心进行,共随机分配382例成人ALS患者(雷夫利珠单抗255例,安慰剂127例)。 interim分析显示第50周ALSFRS-R自基线变化两组无显著差异,试验因无效而终止;主要分析显示CAFS两组无显著差异(P=0.61),治疗中出现的不良事件发生率两组相似。结论认为雷夫利珠单抗未能减缓ALS功能衰退,安全性特征与安慰剂相似。

要点

  • 雷夫利珠单抗组第50周ALSFRS-R自基线变化为-14.67分,安慰剂组为-13.33分,两组差异无统计学显著(差值-1.34分,95%CI -4.21至1.53)。
  • 第50周CAFS两组无显著差异(均值5.5分,95%CI -15.7至26.6,P=0.61)。
  • 治疗中出现的不良事件发生率雷夫利珠单抗组为80.0%(204例),安慰剂组为85.0%(108例)。

核心结论

  • 雷夫利珠单抗未能减缓ALS患者的功能衰退,其安全性与安慰剂相似。
  • 原文指出亟需高效新型治疗以延缓ALS患者功能衰退并延长生存。

研究设计与样本

  • 双盲、安慰剂对照、平行组、多国、随机3期临床试验,于2020年3月30日至2021年10月17日在17个国家81个ALS专科中心开展。
  • 筛选478例,排除96例,最终382例随机分配(雷夫利珠单抗255例,安慰剂127例),按2:1比例分组。
  • 入选标准包括体重≥40 kg、符合El Escorial诊断标准、研究前ALSFRS-R进展评分最低为每月-0.3分。
  • 干预为静脉给予安慰剂或按体重给药的雷夫利珠单抗,每8周一次直至第42周,允许继续标准治疗。
  • 当33%参与者完成第26周时进行预设的非盲非绑定期中无效性分析,条件把握度低于10%则终止试验。

主要发现

  • 期中分析显示第50周ALSFRS-R自基线变化:雷夫利珠单抗组-14.67分(SE 0.89,95%CI -16.42至-12.91),安慰剂组-13.33分(SE 1.22,95%CI -15.72至-10.93),组间差异无统计学显著(差值-1.34分,SE 1.46,95%CI -4.21至1.53)。
  • 基于期中数据,试验因无效而终止。
  • 第50周主要分析显示CAFS两组无显著差异(均值5.5分,SE 10.8,95%CI -15.7至26.6,P=0.61)。
  • 治疗中出现的不良事件发生率:雷夫利珠单抗组204例(80.0%),安慰剂组108例(85.0%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Additional therapies for amyotrophic lateral sclerosis (ALS) are urgently needed. Immune-mediated complement activation may be involved in ALS pathogenesis as evidenced by the upregulation of terminal components; thus, complement inhibition could potentially slow progression. OBJECTIVE: To evaluate the safety and efficacy of the terminal complement C5 inhibitor ravulizumab in adults with ALS. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, placebo-controlled, parallel-group, multinational, randomized, phase 3 clinical trial was conducted from March 30, 2020, to October 17, 2021, in 81 ALS specialty centers across 17 countries. A preplanned, unmasked, nonbinding interim futility analysis was conducted when 33% of participants had completed week 26, wherein a conditional power of less than 10% would halt the trial. A total of 478 individuals were screened, and 96 were excluded. Inclusion criteria were weight of 40 kg or more, fulfillment of the El Escorial diagnostic criteria, and a minimal prestudy Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) progression score of -0.3 points per month. INTERVENTIONS: Study treatment consisted of placebo or a weight-based dose of intravenous ravulizumab every 8 weeks until week 42. Participants could continue standard-of-care treatment. MAIN OUTCOMES AND MEASURES: The primary end point was change from baseline in ALSFRS-R score at week 50 based on the Combined Assessment of Function and Survival (CAFS). RESULTS: A total of 382 participants were randomly assigned 2:1 to receive ravulizumab (n = 255; mean [SD] age, 58.6 [10.6] years; 94 female [36.9%] and 161 male [63.1%]) or placebo (n = 127; mean [SD] age, 58.0 [11.0] years; 58 female [45.7%] and 69 male [54.3%]). The interim analysis showed that the observed mean change from baseline in ALSFRS-R at week 50 was -14.67 points (SE, 0.89 points; 95% CI, -16.42 to -12.91 points) for ravulizumab and -13.33 points (SE, 1.22 points; 95% CI, -15.72 to -10.93 points) for placebo, with no significant difference between the groups (mean [SE] difference, -1.34 [1.46] points; 95% CI, -4.21 to 1.53 points). Based on these data, the trial was terminated for futility. The primary analysis at week 50 showed no significant difference in CAFS between groups (mean [SE], 5.5 [10.8] points; 95% CI, -15.7 to 26.6 points; P = .61). Overall incidence rates for treatment-emergent adverse events were similar for ravulizumab (204 participants [80.0%]) and placebo (108 participants [85.0%]). CONCLUSIONS AND RELEVANCE: This trial rapidly showed that terminal complement C5 inhibition with ravulizumab did not slow functional decline in participants with ALS and that the safety profiles of ravulizumab and placebo were similar. Highly effective, novel treatments are critically needed to slow functional decline and extend survival in patients with ALS. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04248465.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Genge A, van den Berg LH, Frick G, et al. Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Neurol. 2023. PMID: 37695623. doi:10.1001/jamaneurol.2023.2851

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。